ABVX
Abivax S.A.
NASDAQ · Healthcare · Biotechnology · FR
$114.88
+0.74%Institutional positioning
13F filings over the trailing two quarters
New 151Increased 214Reduced 174Sold out 39
| Filer | Action | Shares | Filed |
|---|---|---|---|
| TCG CROSSOVER MANAGEMENT, LLC | Reduced | 6,481,085 | May 15, 2026 |
| TCG Crossover Management, LLC | Reduced | 6,007,834 | Aug 14, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | Increased | 4,647,896 | Aug 14, 2026 |
| UBS GROUP AG | Increased | 4,547,406 | May 5, 2026 |
| CITADEL ADVISORS LLC | Increased | 4,243,752 | Sep 2, 2026 |
| Darwin Global Management, Ltd. | Increased | 3,621,583 | Aug 14, 2026 |
| DARWIN GLOBAL MANAGEMENT, LTD. | Increased | 3,468,657 | May 15, 2026 |
| Helikon Investments Ltd | Increased | 2,787,131 | Aug 11, 2026 |
| Vestal Point Capital, LP | Increased | 2,349,443 | Aug 14, 2026 |
| Jupiter Topco LLC | New Position | 1,913,933 | Aug 14, 2026 |
| UBS Group AG | Reduced | 1,860,618 | Aug 13, 2026 |
| ADAR1 Capital Management, LLC | Increased | 1,849,103 | Aug 14, 2026 |
| MORGAN STANLEY | Reduced | 1,704,958 | May 15, 2026 |
| Caligan Partners LP | Increased | 1,557,924 | Aug 14, 2026 |
| VESTAL POINT CAPITAL, LP | Reduced | 1,500,000 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings